OncoMatch/Clinical Trials/NCT03026140
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
Is NCT03026140 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for colon carcinoma.
Treatment: Nivolumab · Ipilimumab · Celecoxib 200mg · BMS-986253 · BMS-986016 — In this exploratory study, patients with stage 1-3 adenocarcinoma of the colon with no signs of distant metastases will be treated with short-term immunotherapy + novel IO combinations (i.e. anti-IL 8, COX2-inhibitors, anti-LAG3). This treatment will be given during the window period until surgical resection of the tumor. The duration of treatment will be in between approximately 6 and 12 weeks.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Colorectal Cancer
Performance status
WHO 0–1
Prior therapy
Cannot have received: immune checkpoint inhibitor
No previous treatment with immune checkpoint inhibitors targeting CTLA-4, PD-1 or PD-L1
Cannot have received: radiation therapy
No radiotherapy prior to or planned post-surgery radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03026140 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages